Department of Thoracic Oncology, The First Affiliated Hospital, Guangzhou Medical University, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, Guangzhou, China.
The Center for Translational Medicine, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Can Respir J. 2022 Oct 31;2022:6763625. doi: 10.1155/2022/6763625. eCollection 2022.
The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) ( < 0.001). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.
贝伐珠单抗在恶性胸腔积液（MPE）或恶性心包积液（MPCE）中的应用引起了研究人员越来越多的关注，但贝伐珠单抗的具体给药方式仍不清楚。本研究纳入了经组织学或细胞学证实的非小细胞肺癌（NSCLC）伴 MPE 或 MPCE 的患者，在引流积液后，采用低剂量单药贝伐珠单抗（100mg）经胸膜或心包腔内给药。本研究采用肺癌症状量表（LCSS）、疗效和药物治疗的安全性作为评估参数。结果表明，与治疗前相比，治疗后肺癌相关症状明显改善（LCSS，评分 494±78 比评分 377±77，均数±标准差）（<0.001）。恶性积液得到了很好的控制，MPE 和 MPCE 的中位无进展生存期（TTP）分别为 91 天和 111 天。此外，除 1 例患者出现轻度头晕外，未观察到严重的不良反应。总之，低剂量单药（100mg）贝伐珠单抗经胸膜或心包腔内给药治疗肺癌引起的恶性积液是有效且安全的，可迅速改善 NSCLC 患者恶性积液相关症状和生活质量。
